Content

Stock data of the following companies from Oct 2019 is included in this dataset. (BioNTech , Moderna , Johnson & Johnson , Inovio Pharmaceuticals, Sinovac , Sinopharm , Novavax ,Astrazeneca(Oxford)) (The date 2019 was chosen because few companies got IPO just in 2019)

Inspiration

To do more analysis on the performance of the companies with the influence of covid vaccine.

End note

Please let me know if any more companies are to be included or any changes have to be made to improve the quality of the dataset in the discussion section.

About Dataset: WHO COVID-19 Global Data

This dataset provides comprehensive information on the global COVID-19 pandemic as reported to the World Health Organization (WHO). The dataset is available in comma-separated values (CSV) format and includes the following fields:

Daily cases and deaths by date reported to WHO: WHO-COVID-19-global-data.csv

• Date_reported (Date): The date of reporting to WHO.
• Country_code (String): The ISO Alpha-2 country code.
• Country (String): The name of the country, territory, or area.
• WHO_region (String): The WHO regional office to which the country belongs. WHO Member States are grouped into six WHO regions, including AFRO (Regional Office for Africa), AMRO (Regional Office for the Americas), SEARO (Regional Office for South-East Asia), EURO (Regional Office for Europe), EMRO (Regional Office for the Eastern Mediterranean), and WPRO (Regional Office for the Western Pacific).
• New_cases (Integer): The number of new confirmed cases reported on a given day. This is calculated by subtracting the previous cumulative case count from the current cumulative case count.
• Cumulative_cases (Integer): The total cumulative confirmed cases reported to WHO up to the specified date.
• New_deaths (Integer): The number of new confirmed deaths reported on a given day. Similar to new cases, this is calculated by subtracting the previous cumulative death count from the current cumulative death count.- Cumulative_deaths (Integer): The total cumulative confirmed deaths reported to WHO up to the specified date.

In addition to the COVID-19 case and death data, this dataset also includes valuable information related to COVID-19 vaccinations. The vaccination data consists of the following fields:

Vaccination Data Fields: vaccination-data.csv

• COUNTRY (String): Country, territory, or area.
• ISO3 (String): ISO Alpha-3 country code.
• WHO_REGION (String): The WHO regional office to which the country belongs.
• DATA_SOURCE (String): Indicates the data source, which can be either "REPORTING" (Data reported by Member States or sourced from official reports) or "OWID" (Data sourced from Our World in Data COVID-19 Vaccinations).
• DATE_UPDATED (Date): Date of the last update.
• TOTAL_VACCINATIONS (Integer): Cumulative total vaccine doses administered.
• PERSONS_VACCINATED_1PLUS_DOSE (Decimal): Cumulative number of persons vaccinated with at least one dose.
• TOTAL_VACCINATIONS_PER100 (Integer): Cumulative total vaccine doses administered per 100 population.
• PERSONS_VACCINATED_1PLUS_DOSE_PER100 (Decimal): Cumulative persons vaccinated with at least one dose per 100 population.
• PERSONS_LAST_DOSE (Integer): Cumulative number of persons vaccinated with a complete primary series.
• PERSONS_LAST_DOSE_PER100 (Decimal): Cumulative number of persons vaccinated with a complete primary series per 100 population.
• VACCINES_USED (String): Combined short name of the vaccine in the format "Company - Product name."
• FIRST_VACCINE_DATE (Date): Date of the first vaccinations, equivalent to the start/launch date of the first vaccine administered in a country.
• NUMBER_VACCINES_TYPES_USED (Integer): Number of vaccine types used per country, territory, or area.
• PERSONS_BOOSTER_ADD_DOSE (Integer): Cumulative number of persons vaccinated with at least one booster or additional dose.
• PERSONS_BOOSTER_ADD_DOSE_PER100 (Decimal): Cumulative number of persons vaccinated with at least one booster or additional dose per 100 population.

In addition to the vaccination data, a separate dataset containing vaccination metadata is available, including information about vaccine names, product names, company names, authorization dates, start and end dates of vaccine rollout, and more.

Vaccination metadata Fields: vaccination-metadata.csv

• ISO3 (String): ISO Alpha-3 country code
• VACCINE_NAME (String): Combined short name of vaccine: "Company - Product name" (see below)
• PRODUCT_NAME (String): Name or label of vaccine product, or type of vaccine (if unnamed).
• COMPANY_NAME (String): Marketing authorization holder of vaccine product.
• FIRST_VACCINE_DATE (Date): Date of first vaccinations. Equivalent to start/launch date of the first vaccine administered in a country.
• AUTHORIZATION_DATE (Date): Date vaccine product was authorized for use in the country, territory, area.
• START_DATE (Date): Start/launch date of vaccination with vaccine type (excludes vaccinations during clinical trials).
• END_DATE (Date): End date of vaccine rollout
• COMMENT (String): Comments related to vaccine rollout
• DATA_SOURCE (String): Indicates data source - REPORTING: Data reported by Member States, or sourced from official re...

This dashboard provides an overview of the progress in the roll-out of COVID-19 vaccines in adults (aged 18 years and above) across EU/EEA Member States. It presents the number of vaccine doses distributed by manufacturers to each Member State for the different vaccines authorised for use in the EU and the number of first, second or unspecified doses administered to adult individuals. The information is visualized via interactive maps, graphs and tables. In the near future, it will become possible to also download the raw data.

Data are provided by the EU/EEA Member States via the European Surveillance System (TESSy). Member States are requested to report basic indicators (number of vaccine doses distributed by manufacturers, number of first, second and unspecified doses administered) and data by target groups at national level twice a week (every Tuesday and Friday). Data are subject to retrospective corrections; corrected datasets are released as soon as the processing of updated national data has been completed. For more details, see Notes on the data.

This feature layer is part of SDGs Today. Please see sdgstoday.orgThe Launch and Scale Speedometer, led by the Duke Global Health Innovation Center, has tracked COVID-19 vaccine purchase agreements between November 2020 and June 2022. This dataset provides the most recent data on vaccine purchases and negotiations by individual countries and unilateral partnerships from 16 companies. Unilateral partnerships include the African Union, European Union, Latin America excluding Brazil, and COVAX, the global initiative aimed to produce, procure, and distribute vaccines to member countries.So far, 14.9 billion doses have been reserved. Confirmed doses are deals that have been signed and finalized. Potential doses include both deals that are under negotiation (not yet final) and also options for additional doses as part of existing confirmed deals.For more information, contact info@launchandscalefaster.org

This document provides guidance to vaccine manufacturers seeking authorization for their vaccine that targets the SARS-CoV-2 virus. This guidance applies to applications under the interim order respecting the importation, sale and advertising of drugs for use in relation to COVID-19.

Pretax-Margin Time Series for Novavax Inc. Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Owing to the success of linear mRNA coronavirus disease 2019 (COVID-19) vaccines, biopharmaceutical companies and research teams worldwide have attempted to develop more stable circular RNA (circRNA) vaccines and have achieved some preliminary results. This review aims to summarize key findings and important progress made in circRNA research, the in vivo metabolism and biological functions of circRNAs, and research progress and production process of circRNA vaccines. Further, considerations regarding the quality control of circRNA vaccines are highlighted herein, and the main challenges and problem-solving strategies in circRNA vaccine development and quality control are outlined to provide a reference for circRNA vaccine-related research.

The file contains 9,921 tweets labelled with the concerns towards vaccines. There are 3 columns in the file: - ID of the tweet in a string format, appended with a "t" (to make it easier to work with on spreadsheet softwares). - The tweet text - The different labels (vaccine concerns) expressed in the tweet, seperated by spaces.

List of the 12 different vaccine concerns in the dataset: - [unnecessary]: The tweet indicates vaccines are unnecessary, or that alternate cures are better. - [mandatory]: Against mandatory vaccination — The tweet suggests that vaccines should not be made mandatory. - [pharma]: Against Big Pharma — The tweet indicates that the Big Pharmaceutical companies are just trying to earn money, or the tweet is against such companies in general because of their history. - [conspiracy]: Deeper Conspiracy — The tweet suggests some deeper conspiracy, and not just that the Big Pharma want to make money (e.g., vaccines are being used to track people, COVID is a hoax) - [political]: Political side of vaccines — The tweet expresses concerns that the governments / politicians are pushing their own agenda though the vaccines. - [country]: Country of origin — The tweet is against some vaccine because of the country where it was developed / manufactured - [rushed]: Untested / Rushed Process — The tweet expresses concerns that the vaccines have not been tested properly or that the published data is not accurate. - [ingredients]: Vaccine Ingredients / technology — The tweet expresses concerns about the ingredients present in the vaccines (eg. fetal cells, chemicals) or the technology used (e.g., mRNA vaccines can change your DNA) - [side-effect]: Side Effects / Deaths — The tweet expresses concerns about the side effects of the vaccines, including deaths caused. - [ineffective]: Vaccine is ineffective — The tweet expresses concerns that the vaccines are not effective enough and are useless. - [religious]: Religious Reasons — The tweet is against vaccines because of religious reasons - [none]: No specific reason stated in the tweet, or some reason other than the given ones.

Retained-Earnings Time Series for Novavax Inc. Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Attitude on COVID-19 vaccination intention (hierarchical binary logistic regression).

COVID-19 Reopening Data from Associated Press and Kantar Media

Access regularly updated data from The Associated Press and Kantar Media containing information on events at the global, national and state levels as economies reopen following the coronavirus pandemic via AP Planner.

AP Planner is a paid service from The Associated Press & Kantar Media.

The four data files below feature the following event types:

• Environmental, Social and Governance (ESG): Events related the factors that measure the sustainability and societal impact of an investment in a company or business.
• Healthcare, Pharmaceuticals and Bio Tech: Health care providers and services, health care equipment and supplies, and health care technology companies. Drug and vaccine production, as well as biological substances for the purposes of drug discovery and diagnostic development.
• Politics: U.S. political news and events.
• Diversity and Discrimination: News and events related to race, religion, gender, sexuality, disability and age.

All data is compiled by a dedicated staff with over 15 years of forward planning research experience, employing data verification and processes designed to provide reliable and up-to-date information.

The data can be used to help:

• Provide signals to investors on how to act and at what speed based on the types of events returning across industries.
• Analyze risk associated with companies based on when they're reopening.
• Retain your own customer base based on reopening dates for vendors and competitors.
• Track COVID regulations to prepare inventory and guest policies.

The following data files are samples - if you are interested in licensing the full, regularly updated database, please contact Opal Barclay (obarclay@ap.org) at The Associated Press or Click on Request Access Button above.

​

***

FAQs

Why does AP and Kantar compile this data?_ The data is sourced from AP Planner, a product offered by The Associated Press and Kantar Media. AP Planner is a searchable database of future events that is updated daily and intended for research, not publication.

What information does AP Planner contain?_ AP Planner is global in scope and contains more than 100,000 U.S. and international events from the world of news, current affairs, politics, business, lifestyle and more - all searchable up to 12 months ahead.

Where does the information come from?_ AP Planner aggregates listings from tens of thousands of organizations worldwide. Our research staff monitors over 350,000 websites and uses a verity of secondary sources including press releases, corporate announcements and other outlets to ensure accuracy.

How can I be confident of the data's quality and accuracy?_ We have a dedicated research staff with over 15 years of forward planning research experience. They employ data verification and updating processes designed to provide our customers with completely reliable and up-to-date information.

Can I export data into other applications?_ Yes, AP Planner data can be exported as an Excel file or an Outlook calendar file. The data is also accessible via API.

Who can I contact to learn more about AP Planner?_ Opal Barclay, obarclay@ap.org.

The coronavirus pandemic has affected the entire world and many families have been destroyed. The stock exchange was also affected, but vaccine companies took advantage of this moment and leveraged their profits

Biotech companies:

• PFIZER: Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas.

• ASTRAZENECA: Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

• BIONTECH: BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

• MODERNA: Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

• NOVAVAX: Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases.

Check the movement of the financial market through this dataset

Use your creativity and external information

Supplementary Information Files for: Online social endorsement and Covid-19 vaccine hesitancy in the United KingdomWe explore the implications of online social endorsement for the Covid-19 vaccination program in the United Kingdom. Vaccine hesitancy is a long-standing problem, but it has assumed great urgency due to the pandemic. By early 2021, the United Kingdom had the world’s highest Covid-19 mortality per million of population. Our survey of a nationally representative sample of UK adults (N=5,114) measured socio-demographics, social and political attitudes, media diet for getting news about Covid-19, and intention to use social media and personal messaging apps to encourage or discourage vaccination against Covid-19. Cluster analysis identified six distinct media diet groups: news avoiders, mainstream/official news samplers, super seekers, omnivores, the social media dependent, and the TV dependent. We assessed whether these media diets, together with key attitudes, including Covid-19 vaccine hesitancy, conspiracy mentality, and the news-finds-me attitude (meaning giving less priority to active monitoring of news and relying more on one’s online networks of friends for information), predict the intention to encourage or discourage vaccination. Overall, super-seeker and omnivorous media diets are more likely than other media diets to be associated with the online encouragement of vaccination. Combinations of (a) news avoidance and high levels of the news-finds-me attitude and (b) social media dependence and high levels of conspiracy mentality are most likely to be associated with online discouragement of vaccination. In the direct statistical model, a TVdependent media diet is more likely to be associated with online discouragement of vaccination, but the moderation model shows that a TV-dependent diet most strongly attenuates the relationship between vaccine hesitancy and discouraging vaccination. Our findings support public health communication based on four main methods. First, direct contact, through the post, workplace, or community structures, and through phone counseling via local health services, could reach the news avoiders. Second, TV public information advertisements should point to authoritative information sources, such as National Health Service (NHS) and other public health websites, which should then feature clear and simple ways for people to share material among their online social networks. Third, informative social media campaigns will provide super seekers with good resources to share, while also encouraging the social media dependent to browse away from social media platforms and visit reliable and authoritative online sources. Fourth, social media companies should expand and intensify their removal of vaccine disinformation and anti-vax accounts, and such efforts should be monitored by well-resourced, independent organizations.

Abstract: We examine the implications of the very low competitiveness of the Brazilian vaccine RD&I system, which precludes the development of all the important vaccines required by the National Immunization Program (NIP), severely impacting the healthcare of the population. In a country dramatically affected by COVID-19 pandemic and by an exponential increase in emerging and neglected diseases, particularly the poor, these RD&I constraints for vaccines become crucial governance issues. Such constraints are aggravated by a global scenario of limited commercial interest from multinational companies in vaccines for neglected and emerging diseases, which are falling into a “valley of death,” with only two vaccines produced in a pipeline of 240 vaccines. We stress that these constraints in the global pipeline are a window of opportunity for vaccine manufacturers in Brazil and other developing countries in the current paradigm transition towards Vaccinology 4.0. We conclude with recommendations for a new governance strategy supporting Brazilian public vaccine manufacturers in international collaborations for a sustainable national vaccine development and production plan by 2030.

This document provides guidance on establishment licensing, product quality and lot release to bring a COVID-19 vaccine to market in Canada.

Context

The research shows that the U.S. had secured 1.01 billion doses from six different companies up to November 20 which represents the highest quantity of any government apart from India which has made agreements for 1.6 billion. Pfizer/BioNTech and Moderna both account for 100 million U.S. doses each while the U.S. is also set for 500 million doses of the vaccine being developed by the University of Oxford and AstraZeneca.

https://www.statista.com/chart/23660/umber-of-doses-of-covid-19-vaccines-secured-by-the-us/

Content

This chart shows the number of doses of Covid-19 vaccines secured by the U.S. as of November 20, 2020.

Acknowledgements

Niall McCarthy, Data Journalist.

https://www.statista.com/chart/23660/umber-of-doses-of-covid-19-vaccines-secured-by-the-us/

Inspiration

Covid-19 Pandemic.

BackgroundCoronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings.MethodsWe performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information.ResultsSignificant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR).ConclusionsThe study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines.

Barriers to COVID-19 vaccination from semi-structured interviews (n = 29).

Content

The data presented in the Vaccine Tracker are submitted by European Union/European Economic Area (EU/EEA) countries to ECDC through The European Surveillance System (TESSy) twice a week (Tuesdays and Fridays). EU/EEA countries report aggregated data on the number of vaccine doses distributed by manufacturers to the country, the number of first, second and unspecified doses administered in the adult population (18+) overall, by age group and in specific target groups, such as healthcare workers (HCW) and in residents in long-term care facilities (LTCF). Doses are also reported by vaccine product. The downloadable data files contain the data on the COVID-19 vaccine rollout mentioned above and each row contains the corresponding data for a certain week and country. The file is updated daily. Data are subject to retrospective corrections; corrected datasets are released as soon as processing of updated national data has been completed. You may use the data in line with ECDC’s copyright policy.

• YearWeekISO: Date when the vaccine was received/administered. Only weeks are allowed (e.g. “2021-W01”). [yyyy-Www]
• ReportingCountry: ISO 3166-1-alpha-2 two-letter code
• Denominator: Population denominators for target groups (total population and agespecific population denominators do not need to be reported and will be obtained from Eurostat/UN). Denominators only need to be reported for TargetGroup = “HCW” and TargetGroup = “LTCF”. They should be reported every week for these target groups. [Numeric]
• NumberDosesReceived: Number of vaccine doses distributed by the manufacturers to the country during the reporting week. [Numeric]
• FirstDose: Number of first dose vaccine administered to individuals during the reporting week. [Numeric]
• FirstDoseRefused: Number of individuals refusing the first vaccine dose.[Numeric]
• SecondDose: Number of second dose vaccine administered to individuals during the reporting week.[Numeric]
• UnknownDose: Number of doses administered during the reporting week where the type of dose was not specified (i.e. it is not known whether it was a first or second dose).[Numeric]
• Region: As a minimum data should be reported at national level (Region = country code). Country/NUTS1 or 2/GAUL1/Country specific

• TargetGroup: Target group for vaccination. As a minimum the following should be reported: “ALL” for the overall figures, “HCW” for healthcare workers and age-groups (preferably using the detailed age-groups) ALL = Overall HCW = Healthcare workers LTCF = Residents in long term care facilities Age18_24 = 18-24 year-olds Age25_49 = 25-49 year-olds Age50_59 = 50-59 year-olds Age60_69 = 60-69 year-olds Age70_79 = 70-79 year-olds Age80+ = 80 years and over AgeUnk = Unknown age 1_Age<60 = below 60 years of age 1_Age60+ = 60 years and over

• Vaccine: Name of vaccine. Additional vaccines will be added on approval or as requested. COM = Comirnaty – Pfizer/BioNTech MOD = mRNA-1273 – Moderna CN = BBIBV-CorV – CNBG SIN = Coronavac – Sinovac SPU = Sputnik V - Gamaleya Research Institute AZ = AZD1222 – AstraZeneca UNK = UNKNOWN

• Population: Age-specific population for the country [Numeric]

##

Acknowledgements

European Centre for Disease Prevention and Control

Stock Price Time Series for Beijing Wantai Biological Pharmacy Enterprise Co Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells vitro diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. It also provides HPV, hepatitis E, and nasal spray COVID-19 vaccine. In addition, the company offers bio-immune and immunoassay instruments, as well as automated production lines. Further, it provides bio-immune assays, including hepatitis virus, P85-Ab, TB-IGRA, and biochemical gastric tests, as well as support services. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. operates as a subsidiary of Yangshengtang Co., Ltd.